Amicus Therapeutics, Inc. (FOLD) financial statements (2020 and earlier)

Company profile

Business Address 1 CEDAR BROOK DRIVE
CRANBURY, NJ 08512
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:453504359330214169
Cash and cash equivalents14380491876924
Short-term investments310424310  128
Other undisclosed cash, cash equivalents, and short-term investments   14314518
Receivables332291  
Inventory, net of allowances, customer advances and progress billings14853  
Inventory14853  
Other current assets    33
Other undisclosed current assets2017195(0)(18)
Total current assets:520551392340217155
Noncurrent Assets
Operating lease, right-of-use asset33
Property, plant and equipment481191063
Long-term investments and receivables     17
Long-term investments     17
Intangible assets, net (including goodwill)22122122168468435
Goodwill19819819819819812
Intangible assets, net (excluding goodwill)23232348748723
Other noncurrent assets2875211
Total noncurrent assets:33023923569769255
TOTAL ASSETS:8507906271,037908210
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1208154413216
Accounts payable227813166
Accrued liabilities16111485 
Employee-related liabilities2722201065
Taxes payable7     
Interest and dividends payable440   
Other undisclosed accounts payable and accrued liabilities4537121045
Debt7    4
Deferred compensation liability     0
Business combination, contingent consideration, liability  85641 
Other undisclosed current liabilities16814 (0)
Total current liabilities:12986701117420
Noncurrent Liabilities
Long-term debt and lease obligation2033221641544211
Long-term debt, excluding current maturities1503221641544211
Operating lease, liability54
Liabilities, other than long-term debt3323263914101
Deferred compensation liability, classified   21 
Deferred tax liabilities, net 6174176 
Deferred income tax liabilities5
Other liabilities532211
Business combination, contingent consideration, liability232017214233 
Other undisclosed noncurrent liabilities917    
Total noncurrent liabilities:24536119054545211
Total liabilities:37444726065652531
Stockholders' equity
Stockholders' equity attributable to parent476343353360348122
Common stock322111
Additional paid in capital2,2271,7401,4011,120917569
Accumulated other comprehensive income (loss)30(2)2(0)(0)
Accumulated deficit(1,769)(1,412)(1,064)(780)(580)(447)
Warrants and rights outstanding121316169 
Total stockholders' equity:476343353360348122
Other undisclosed liabilities and equity  14203557
TOTAL LIABILITIES AND EQUITY:8507906271,037908210

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues18291375 1
Revenue, net375 1
Cost of revenue
(Cost of Goods and Services Sold)
(22)(14)(6)(1)  
Gross profit:16077314 1
Operating expenses(464)(406)(473)(186)(130)(70)
Operating loss:(304)(329)(442)(182)(130)(69)
Nonoperating income (expense)8210(5)(0)0
Investment income, nonoperating10104  0
Foreign currency transaction loss, before tax (3)    
Other nonoperating income (expense)(3)(6)6(5)(0)(0)
Interest and debt expense(59)(22)(17)(5)(2)(1)
Other undisclosed loss from continuing operations before equity method investments, income taxes    (0) 
Loss from continuing operations before equity method investments, income taxes:(356)(349)(449)(192)(132)(70)
Other undisclosed loss from continuing operations before income taxes   (12)  
Loss from continuing operations before income taxes:(356)(349)(449)(204)(132)(70)
Income tax expense (benefit)(0)01654 1
Net loss available to common stockholders, diluted:(356)(349)(284)(200)(132)(69)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(356)(349)(284)(200)(132)(69)
Other comprehensive loss(0)  (1)  
Comprehensive loss:(357)(349)(284)(201)(132)(69)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent33(4)30(0)
Comprehensive loss, net of tax, attributable to parent:(354)(346)(288)(198)(132)(69)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: